Chairs Sven Mahner (Germany) Antonio González-Martín (Spain)

Slides:

Advertisements

Similar presentations

UCSF School of Medicine OCME Program Frequently Asked Questions Faculty Disclosure and Resolution of Conflict of Interest.

Advertisements

Effective Use of Insulin in Diabetes: Update for 2007

Michael Birrer, PI, Director, Gynecologic Medical Oncology, MGH Lari Wenzel, Co-PI, Prof. of Medicine, University of California, Irvine

Standards for Commercial Support: Standards to Ensure Independence in CME Activities SM Case Studies.

Individualizing Care in HIV: A Critical Review of Treatment Options Presented by The Johns Hopkins University School of Medicine Produced in collaboration.

ISLLC Standard #1 ISLLC Standard #1 Planning School Improvement Name: Planning School Improvement that Ensures Student Success Workshop Facilitator.

ISLLC Standard #4 ISLLC Standard #4 Monitoring Diverse Needs Name Workshop Facilitator.

Clinical Psychology at the University of Hull Dr Nick Hutchinson Dr Emma Wolverson Dr Annette Schlösser Doctoral Course in Clinical Psychology, Faculty.

Training of forensic psychiatrists – the Ghent group Per Lindqvist, MD, Associate Professor Division of Forensic Psychiatry Department of Clinical Neuroscience.

ISLLC Standard #6 Monitoring Education Stakeholders Name Workshop Facilitator.

17:00 – 19:00 | Sunday, 30 June, 2013 Session Room 3 Kuala Lumpur Convention Centre (KLCC) Kuala Lumpur, Malaysia Chair: Nicholas Paton.

WHO Collaborating Centre Evidence-Based Health Promotion in Hospitals & HS Bispebjerg University Hospital Welcome and introduction Shu-Ti Chiou MD PHD.

ISLLC Standard #6 ISLLC Standard #6 Implementing Educational Policy Name Workshop Facilitator.

Program Coordinator Medication Assistance Program Smilow Cancer Hospital at Yale New Haven Program Coordinator Medication Assistance Program Smilow Cancer.

ISLLC Standard #3 Implementing Effective Meetings Name Workshop Facilitator.

Welcome to OTL541K! Week 2 Live Classroom. Let’s Get Started! Agenda: Introductions The big picture and course topics Review of course expectations Your.

Angelo Di Leo “Sandro Pitigliani” Medical Oncology Department Hospital of Prato Istituto Toscano Tumori, Prato, Italy Adjuvant hormone therapy in post-menopausal.

Darren Cunningham CEO Presentation by Darren Cunningham CEO

Lessons Learnt The demise of thoracic surgery (Part II)

PARP INHIBITION IN OVARIAN CANCER

Disclosure In relation to this presentation, I declare the following, real or perceived conflicts of interest: - A conflict of interest is any situation.

2nd Bench – Can Core Group Meeting Welcome and introduction

COI Disclosure Name of First Author

(Used, with permission, of Dr Thomas Cremer, Department of Biology II, Anthropology and Human Genetics, Ludwig Maximilian University, Munich, Germany.)

Ovarian Cancer (C56 C57.0-C57.7):

Best of ASCO Series: Oncology Grand Rounds

Drug-Drug Interactions in Older Cancer Patients

Oncology Grand Rounds “Potentially Lethal Prostate Cancer:

Professor Daniel Palmer Chair Medical Oncology NWCR, Dr Syed Hussain Clinical Senior Lecturer, Medical Oncology, University of Liverpool invite you to:

Managing symptomatic asthma in primary care: The personalised approach

IOPBS2016 “Respect to Oncology, Optimism in Reconstruction”

An Introduction to DNA Damage Repair in Cancer: Beyond PARP

Relevant Financial Disclosure(s)

PARP Inhibition: The New Frontier in Recurrent Ovarian Cancer

The Nurse View.

The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow chart summarising the process for the identification of eligible studies.

Conflict of Interest Disclosure Form

Turid Heiberg1,2, Bart Baekelandt3,

Conflict of Interest Disclosure:

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data.

The Japan Diabetes Society

Maintenance Therapy in Advanced Ovarian Cancer

An Introduction to NRG Oncology

Conclusion Dr Antonio González Martín Head of Medical Oncology

The Japanese Society for Helicobacter Research COI

(A) Safety profile overview.

MAINTENANCE THERAPY WITH PARP INHIBITORS

Dr Axel Walther Head of Research Bristol Cancer Institute UK

For the ACTION study group

EVOLUTION OF PARP INHIBITORS IN OVARIAN CANCER

Title Author1 Introduction Results and discussion Conclusion

Agenda Registration 8.30 am Welcome and Introductions 9.00 am

COI Disclosure STRUCTURE CLUB JAPAN Name of First Author

Disclosures The project was funded from the following sources:

Conflict of Interest Disclosure Form

Presenter Disclosure Dr. First Name Last Name – Presenter

COI Disclosure Japan Diabetes Society

The Japan Diabetes Society

(A) Progression-free survival in the hormone receptor-negative cohort patients treated with PARPi versus those treated with mono chemotherapy (controls).

Rol de la IO en el Tratamiento del Cáncer Renal: CheckMate 214

What Does BRCA Have to Do With It? PARP Inhibitors in Ovarian Cancer

Objective response rate in patients with BRCA-mutated HER2-negative breast cancer treated with PARPi versus those treated with monochemotherapy (controls).

TITLE & AUTHORS Presenter Name, Institution, Country.

Financial Disclosure Financial Interest / Affiliation

Overall trends in CD4 counts and plasma viremia in an urban clinic since the introduction of highly active antiretroviral therapies J.C. Martín, V Soriano,

(A) Progression-free survival in patients with BRCA-mutated HER2-negative breast cancer treated with PARPi versus those treated with monochemotherapy (controls).

Dr Garima Srivastav MD,DNB, MNAMS,MRCOG Consultant Obs & Gynae, Specialist in Endoscopy & Cosmetic Gynaecology at ORANGE KLINIC, Delhi Director ORANGE.

Name of Activity / Session

Conflict of Interest Disclosure Form

The Japanese Society for Helicobacter Research COI

Presentation transcript:

Chairs Sven Mahner (Germany) Antonio González-Martín (Spain) CHANGING THE NATURAL DISEASE COURSE IN OVARIAN CANCER – the role of PARPi maintenance Chairs Sven Mahner (Germany) Antonio González-Martín (Spain) ESMO 2018 Munich, Germany

WELCOME & INTRODUCTION Prof Dr Sven Mahner, MD Chair and Director Department of Obstetrics & Gynaecology University Hospital Munich, Ludwig-Maximilians-University, Munich, Germany

Faculty and disclosures Prof Dr Sven Mahner Munich, Germany Dr Rebecca Kristeleit London, UK Financial support, honoraria and grants from: AstraZeneca, Bayer, Clovis, GSK, Medac, MSD, Pharmamar, Roche, Sensor Kinesis, Tesaro, Teva AstraZeneca, Clovis, InCyte, Roche, TESARO Dr Antonio González-Martín Madrid, Spain Dr Axel Walther Bristol, UK AstraZeneca, Clovis Oncology, Roche, TESARO Educational grant from AstraZeneca, consulting fee and educational grants from TESARO Dr Maurizio D’Incalci Milan, Italy Scientific boards and consultancy for TESARO and Pharma Mar

Housekeeping ASK-THE-FACULTY.COM/ESMO2018 Please silence mobile phones We look forward to your questions… … ask the faculty online!

Agenda Time Presentation Presenter 13:00 – 13:15 Welcome and Introduction Evolution of PARPi in ovarian cancer Sven Mahner 13:15 – 13:35 Examining the relevant facts and new insights on PARP inhibition Maurizio D’Incalci 13:35 – 13:45 Maintenance therapy with PARPi 13:45 – 14:05 Presenting the latest clinical evidence on PARPi in maintenance therapy Rebecca Kristeleit 14:05 – 14:25 Practical experience with PARPi in ovarian cancer maintenance Axel Walther 14:25 – 14:35 Conclusion Antonio González-Martín

Symposium objectives Review the concept of maintenance therapy in ovarian cancer Differentiate the available PARP inhibitors Examine clinical study evidence on PARP inhibitors Discuss PARP inhibitor maintenance therapy in clinical practice